{"id":"W4392482408","doi":"10.1016/j.ygyno.2024.01.045","title":"Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer","year":2024,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University; McGill University Health Centre","funders":"ImmunoGen","keywords":"Medicine; Bevacizumab; Carboplatin; Conjugate; Ovarian cancer; Antibody-drug conjugate; Folate receptor; Antibody; Oncology; Drug; Pharmacology; Internal medicine; Cancer research; Cancer; Monoclonal antibody; Chemotherapy; Immunology; Cisplatin; Cancer cell","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001369595,0.0010228,0.002291848,0.000315479,0.0003478286,0.0007166318,0.0006493501,0.00110778,0.003077917],"category_scores_gemma":[0.0009416685,0.0006883364,0.000991736,0.000347626,0.0004868094,0.0006577793,0.0003009502,0.002375877,0.000757446],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008697469,"about_ca_system_score_gemma":0.00128582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008892856,"about_ca_topic_score_gemma":0.002456933,"domain_scores_codex":[0.9994753,0.0002579209,0.00003404079,0.00009906582,0.00006057505,0.00007310893],"domain_scores_gemma":[0.9993526,0.00006977921,0.000163218,0.0000488611,0.00004905669,0.0003164712],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7303056,0.06877549,0.01089825,0.001020991,0.002470411,0.0002652291,0.0004378865,0.00247808,0.08077084,0.0001868949,0.002828996,0.09956131],"study_design_scores_gemma":[0.5046895,0.4695165,0.01696177,0.00002830724,0.0005124013,0.0003419098,0.00005696427,0.00135462,0.004143279,0.00009985391,0.002269021,0.00002581352],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944984,0.001591187,0.0005299008,0.0002419351,0.00006626745,0.001795744,0.0004546972,0.00006870724,0.0007531933],"genre_scores_gemma":[0.9930165,0.0009254204,0.00142538,0.0004181086,0.00008162223,0.001566047,0.0009280037,0.00002805623,0.001610879],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003077917,"threshold_uncertainty_score":0.0102967,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0111091942545518,"score_gpt":0.3107141787606278,"score_spread":0.299604984506076,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}